SVB Securities analyst Mani Foroohar downgraded Decibel Therapeutics to Market Perform from Outperform with a price target of $2, down from $7. The firm cites uncertainty for the partnering opportunity for DB-020 and broader concerns regarding cash burn and runway for the downgrade, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DBTX:
- Decibel downgraded to Market Perform from Outperform at SVB Securities
- Decibel Therapeutics reports Q4 cash position $104.6M vs $162.3M last year
- Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
- Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
- Frequency’s failure highlights Decibel’s differentiation, says H.C. Wainwright
